CHRM1 and schizophrenia: These trials included phase II and III trials showing the efficacy of KarXT, which is predicted to having its therapeutic benefits from the inclusion of CHRM1/CHRM4 dual agonism, against the positive and negative symptoms of schizophrenia (Brannan et al., 2021).